MSR1 and glioblastoma: To assess whether CD204 targeting can be combined with immune checkpoint targeting, the expression of immune checkpoint‐related genes in glioma and GBM, namely CD274 (PD‐L1), PDCD1 (PD‐1), HAVCR2 (TIM‐3), LAG3, CD276 (B7‐H3), and VTCN1 (B7‐H4) was assessed in the CGGA and TCGA datasets.